NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. Misleading claims represent both a threat to public health and a violation of consumer access to accurate information.”

CBD 296

CBD Clinical Trials Data Treatment 296

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

OCTOBER 6, 2021

Flora will conduct thorough due diligence and honor the traditional FDA and NHS route in scientific processes to ensure consistency, quality, and delivery of cannabinoids for specific disease conditions, backed by data, with an initial focus on fibromyalgia, brain health, pain, and related research. Visit www.floragrowth.ca

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. & Notice of 2021 Final Results.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. For further information please visit out website: www.globalwellnessstrategies.com. from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 191

Clinical Trials Chronic Pain Data Treatment 191

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. This study looked at major cannabinoids such as THC and their accuracy and effectiveness in treating the effects of nausea and vomiting.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JANUARY 6, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. For further information about Anebulo, please visit www.anebulo.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Business 52

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

The Joint Blog

MARCH 18, 2021

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS). Additional information on cannabis and PTSD is available from NORML.

Cannabinoids 26

Cannabinoids Patients Clinical Trials Research and Development 26

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Missing Information. While lengthy, there is a surprising amount of missing information in the study.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

The Cannigma

APRIL 12, 2023

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. While CBN is often marketed as “the sleep cannabinoid ,” the reality is more complicated. Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. Has CBN been proven to help with sleep?

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Del Morgan & Co.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

JULY 4, 2019

The manuscript is part of EMMAC’s collaboration with Imperial College London, forged to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Otherside Farms

JANUARY 25, 2019

Scientists hope to perform human trials in the near future. Researchers at the University of Nottingham conducted a meta-analysis of previous studies, reports the Nottingham Post, concluding that cannabinoids could reduce the severity of stroke as well as improve neurological outcomes.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

OCTOBER 5, 2021

is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Rex Merchant.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

AUGUST 10, 2022

The lead investigators are Jacobo Mintzer , MD, MBA, Brigid Reynolds , ANP-BC, and the Alzheimer’s Clinical Trial Consortium (ACTC).The ” Study Details – provided by Alzheimer’s Clinical Trial Consortium. BARRIE, ON , Aug. 9, 2022 /CNW/ – MediPharm Labs Corp. MediPharm Labs Corp.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., Research opportunities such as the ORR expand the existing scientific knowledge base to better inform clinical decision making, and also dispels the stigma surrounding medicinal cannabis use.”.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

The Cannigma

MARCH 18, 2021

Taken together, the lack of guidance and lack of information about what treatments patients are taking, may underlie “inconsistencies in both use and reported effectiveness,” the researchers stated. Where do Parkinson’s patients get information about cannabis? Here are the most interesting statistics from the survey. Of the 43.9%

Patients 138

Patients Clinical Trials Treatment Cannabis 138

Cannabis Law Report

JANUARY 11, 2022

DENVER–(BUSINESS WIRE)– Ripple , Colorado’s trusted cannabis edibles brand and pioneer of fast-acting and clinically proven technology, is leading the way in cannabis wellness with new Ripple Sleep QuickDissolves and Ripple Sleep QuickGummies. Our mission is to improve people’s lives through cannabinoids.

THC 52

THC Clinical Trials Research and Development Sleep 52

The Cannigma

FEBRUARY 2, 2021

“[Parkinson’s disease (PD)] patients fulfilling these criteria are entitled to be prescribed medical cannabis, but there are few data about which type of cannabinoid and which route of administration might be promising for which PD patient, and which symptoms. The effectiveness of cannabis for Parkinson’s disease. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

FEBRUARY 2, 2022

The double-blind, randomised, placebo-controlled clinical trial took place over two years between 2017 and 2019 at the Center for Medicinal Cannabis Research at the University of California. medical cannabis users at risk of unfair prosecution, according to a report by Volteface.

Medicine 52

Medicine Clinical Trials Consumption Sleep 52

Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Medicinal Marijuana Association

FEBRUARY 11, 2024

The anti-inflammatory properties of certain cannabinoids in cannabis could also play a role in protecting retinal cells from damage associated with the condition. Studies have shown that cannabinoids, the active compounds in cannabis, may help decrease intraocular pressure by facilitating better fluid drainage from the eye.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

JULY 26, 2021

OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., For more information, please visit: www.skyebioscience.com. Dr. Skye Bioscience Inc.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

PrestoDoctor

SEPTEMBER 15, 2023

By interacting with the ECS, cannabinoids found in cannabis, such as THC (tetrahydrocannabinol) and CBD (cannabidiol), have the potential to modulate the functioning of this system and alleviate symptoms associated with OCD. Cannabis contains cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), which interact with the ECS.

Research and Development 105

Research and Development Therapy Treatment Strains 105

Cannabis Law Report

SEPTEMBER 14, 2021

A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”. About Radicle Science. Radicle Science is a transformative healthtech B-corp offering the first ever path to natural product validation at scale.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52